FFS
CHRS icon

Founders Financial Securities’s Coherus Oncology CHRS Stock Holding History

Founders Financial Securities’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$20.6K – 494
2025
Q1 		$20.6K Buy
20,000
+10,000
+100% +$11.5K ﹤0.01% 457
2024
Q4 		$13.8K Buy
+10,000
New +$11.2K ﹤0.01% 433

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Founders Financial Securities's CHRS Position: Q2 2025 in Review

Founders Financial Securities sold out of Coherus Oncology (CHRS) in Q2 2025, closing a stake of 20,000 shares — an estimated $20.6K sold.

Founders Financial Securities first reported a position in CHRS in Q4 2024 and held it in 2 quarters. The position peaked at $20.6K in Q1 2025. 112 funds tracked by Wall St. Rank hold CHRS as of Q2 2025.

  • Founders Financial Securities reported no remaining Coherus Oncology position as of Q2 2025 after selling out during the quarter.
  • Founders Financial Securities sold 20,000 Coherus Oncology shares in Q2 2025, an estimated $20.6K.
  • Founders Financial Securities first reported a position in Coherus Oncology in Q4 2024 and held it in 2 quarters.
  • Founders Financial Securities's Coherus Oncology position peaked at $20.6K in Q1 2025.
  • 112 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2025.

Based on Founders Financial Securities's 13F filing for Q2 2025, filed 6 Aug 2025.